IL156733A

Process for the preparation of 2-oxazolidinone derivatives, intermediates for such process and their preparation and the use of the said derivatives in the manufacture of compositions for use in medicine

Abstract

This record has no abstract on file.

Term

No projected expiry on record.

  1. Priority
  2. Filed
  3. Published
  4. Today

20 claims: 9 independent, 11 dependent

  1. 1
    156733/2 1. A process for the preparation of a (S)-4- {[3-[2(dimethylamino)ethyl]- lH-indol-5-yl]methyl}-2-oxazolidinone represented by formula (I):which process comprises the steps of a) forming a carbamate from methyl 4-nitro-(L)-phenylalaninate hydrochloride, represented by formula (II) by adding sodium carbonate or sodium hydrogen carbonate and n-butyl chloroformate and reacting to give methyl(S)-N-butoxycarbonyl-4-nitrophenylalaninate, represented by formula (III) 156733/2 22 b) reducing the compound of formula (III) to give methyl (S)-N-butoxycarbonyl-4-amino phenylalaninate, represented by formula (IV) (IV) c) reducing the methyl ester grouping -CO2CH3 in the compound of formula (IV) to -give (S)-N-butoxycarbonyl-4-aminophenylalaninol, represented by formula (V) d) a ring closure of the compound of formula (V) to give (S)-4-(4-aminobenzyl)-2-oxazolidinone, represented by formula (VI) (VI) e) preparation of the diazonium salt of the compound of formula (VI) followed by reduction to give the hydrazine (S)-4-(4-hydrazinobenzyl)-2-oxazolidinone hydrochloride, represented by formula (VII) 156733/2 23 f) Fischer reaction of the compound of formula (VII) to give the compound of formula (I): wherein steps a) to d) are carried out by a one pot procedure followed by isolation of the compound of formula (VI) and then a second one pot procedure for steps e) and f).
  2. 10
    An intermediate of formula (III)
  3. 11
    An intermediate of formula (IV)
  4. 12
    An intermediate of formula (V) 156733 25
  5. 13
    A process for the preparation of a compound of formula (III) which process comprises reacting a compound of formula (II) with sodium carbonate and n-butylchloroformate (Π)
  6. 14
    A process for the preparation of a compound of formula (IV) • (IV) which process comprises reducing a compound of formula (III) 156733 26
  7. 15
    A process for the preparation of a compound of formula (V) which process comprises reduction of a compound of formula (IV)
  8. 16
    A process for the preparation of a compound of formula (VI) (VI) which process comprises a ring closure of a compound of formula (V) 156733 27
  9. 20
    Use as claimed in any one of Claims 17 to 19 wherein the composition is for use in the treatment and prophylaxis of migraine. , crrixan rwzn arn pnow pnszn irn nr “|»ob ,Ρ’ηη ηχΰ- πώοβπβ mzrna π^πιώώ np’ioz .zruwan ms rnp’nn pmi1? oxnm □ιηπη Pi? _____88°4003 01 J' ·®O? 08513540200 .(moiB nzrnn) cras 'an nwa